Form 4 for IMNM Immunome Inc.
Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-21 · accession 0001415889-24-027601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-25 | 2024-11-21+ | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | P - Purchase | $9.62 | +100.0K | 519.6K | +24% | +$962.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-21 | P | A | 66,057 | $9.54 | 485,693 | D | — | — | (F1) The weighted average purchase price for the transaction report was $9.5412, and the range of prices were between $9.41 and 9.68. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-11-22 | P | A | 33,943 | $9.78 | 519,636 | D | — | — | (F2) The weighted average purchase price for the transaction report was $9.7787, and the range of prices were between $9.41 and $9.90. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |